Zargari Omid, Azimi Seyyede Zeinab, Geranmayeh Siamak
Dana Clinic, Rasht, Iran.
Department of Dermatology, Guilan University of Medical Sciences, Rasht, Iran.
Dermatol Ther. 2017 Jul;30(4). doi: 10.1111/dth.12509. Epub 2017 Jun 19.
Basal cell carcinoma (BCC) is the most common skin cancer but usually has a good prognosis. However, there is a subset of BCC cases with a less favorable prognosis. For patients with locally advanced, recurrent or metastatic BCCs who are not suitable for surgery or radiotherapy, small-molecule drug inhibitors of hedgehog pathway are a new therapeutic opportunity. Here, we present a case of infiltrative BCC with multiple recurrences. Wide excision with reconstructive plastic surgery was performed initially with adjuvant radiotherapy. Due to multiple recurrences afterward, radiotherapy, topical imiquimod and oral itraconazole were used but were not effective. Finally, the patient was treated with vismodegib which led to a complete response. Moreover, the patient's symptoms due to the locally diffused cancer resolved.
基底细胞癌（BCC）是最常见的皮肤癌，但通常预后良好。然而，有一部分BCC病例预后较差。对于局部晚期、复发或转移性BCC且不适合手术或放疗的患者，刺猬通路的小分子药物抑制剂是一种新的治疗选择。在此，我们报告一例浸润性BCC伴多次复发的病例。最初进行了广泛切除并联合整形重建手术及辅助放疗。此后由于多次复发，使用了放疗、外用咪喹莫特和口服伊曲康唑，但均无效。最后，患者接受维莫德吉治疗，实现了完全缓解。此外，患者因局部扩散癌引起的症状也得到缓解。
